The Female Health Company – Cheap Stock to Fight Zika

In Monday’s Goldman Guide we pointed out that we expect this August to be the normal bear that it historically has been. Yesterday, we got a bit of relief with a slight uptick in US markets. It may be time to look for an investment ‘buy and hold’ theme.

The Zika virus is front page material and has made its way into the United States. Several of our athletes, particularly in outdoor sports like golf, have declined to go to Rio over the growing Zika epidemic there.

The Female Health Corporation (NASDAQ – FHCO - $1.35) is a relatively cheap stock with that is currently trading above its 25-day EMA as illustrated in the chart below.

FHCO 6-Month Chart, 25 Day EMA

(Source: www.otcmarkets.com)

The Female Health Company develops, manufactures, and markets consumer health care products. It offers the FC2 female condom that provides women dual protection against unintended pregnancy and sexually transmitted infections, including HIV/AIDS. The Company sells its products to global agencies, non-government organizations, ministries of health, and other government agencies directly, as well as through distribution agreements and other arrangements with commercial partners. It operates in South Africa, Angola, Uganda, Nigeria, Zimbabwe, Tanzania, the United States, the United Kingdom, Brazil, Malaysia, the Democratic Republic of the Congo, and internationally.

Currently there are no drugs or vaccines available to treat Zika. Female condoms are considered a healthy choice to help limit the spread of the disease, since the virus can be transmitted through sexual contact. The U.S. Centers for Disease Control is recommending those who live in a state or area with the mosquito that spreads Zika virus to create a prevention kit. The suggested kit includes a bed net, standing water treatment tabs, insect repellent and the FC2 condoms. The threat of Zika in the US is boosting demand for the Female Health Company’s FC2 and additionally the Ministry of Health in Brazil is planning to dispense 100,000 FC2 female condoms to athletes participating in the 2016 Summer Olympics in Rio de Janeiro.

An impressive metric on the technical side is the short float of only 1.2% for FHCO. Additionally, the Company has $3.2 million on cash with zero debt as of the end of 2Q 2016. Finally, the margins are extremely impressive with 10.9% profit margin and 15.9% operating margin.

With the inevitable increased demand for The Female Health Company’s FC2 condom to fight Zika and the impressive metrics we pointed out, the time is right to buy into FHCO. Look for the stock to climb back to $2.00 by the middle of Q4.

Have a great day!

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.

ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com